YU241279

Overview

YU241279 is an orally active CXCR5 inhibitor. YU241279 inhibits CXCL13 -mediated Gαq -dependent calcium influx and Gαi2 -dependent cAMP reduction in CXCR5 -expressing cells. YU241279 inhibits the proliferation of CXCR5 -expressing lymphoma cells. YU241279 reduces tumor burden in the peripheral blood and bone marrow of mice implanted with lymphoma tissues. YU241279 is well tolerated during oral administration in mice, maintains stable plasma drug concentrations, and shows no metabolic changes. YU241279 can be used in the research of angioimmunoblastic T-cell lymphoma and Burkitt B-cell lymphoma.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > CXCR

Product Information

• Catalog No.: HY-182774
• CAS No.: 1092445-63-0
• Molecular Formula: C22H25NO3
• Molecular Weight: 351.44
• Purity: 99.58%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (7.11 mM); Clear solution
• Availability: In-stock

Source

Original product source